GI Insights

Today, obesity treatment often combines medical and surgical strategies rather than following a strict step-by-step approach. GLP-1 therapies, older medications, and procedures like sleeve gastrectomy and gastric bypass all have a place in an individualized, patient-centered plan. Joining Dr. Peter Buch to discuss how we can integrate these approaches into obesity care is Dr. Devika Umashanker, Program Director of the Obesity Medicine Fellowship at Hartford HealthCare and an Associate Professor of Internal Medicine at the Frank H. Netter MD School of Medicine at Quinnipiac University.

Obesity is one of the biggest drivers of metabolic dysfunction-associated steatotic liver disease (MASLD), and the two conditions often need to be managed together. To get patients the results they need, clinicians must know how to screen effectively, rule out other liver conditions, and match treatment to disease stage. On this episode of GI Insights, Dr. Peter Buch talks with Dr. David Tendler about how to approach these decisions in everyday practice. Dr. Tendler is part of the clinical faculty at the Duke University Department of Medicine in Durham, North Carolina.

Inflammatory bowel disease (IBD) care has shifted from managing symptoms to preventing the long-term consequences of inflammation that a patient may not feel. In this episode of GI Insights, Dr. Peter Buch speaks with Dr. Harish Gagneja about proactive IBD management, from monitoring disease control between colonoscopies and tailoring colorectal cancer surveillance to preventing postoperative Crohn’s recurrence and VTE in hospitalized patients. Dr. Gagneja is a board-certified gastroenterologist in Austin, Texas.

Gastric cancer risk in the United States varies substantially across populations, yet prevention remains largely based on symptoms. Join Dr. Peter Buch and Dr. Chul Hyun, Director of the Gastric Cancer Prevention and Screening Program at the Yale School of Medicine, as they explore how recognizing key risk factors may help us identify patients who warrant closer evaluation.

The American Society for Gastrointestinal Endoscopy (ASGE) recently released a new guideline on when to use endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) in managing early esophageal and gastric cancers. To learn more about when to use each approach, Dr. Peter Buch sits down with guideline co-author Dr. Vivek Kaul. Dr. Kaul is also the Segal-Watson Professor of Medicine at the University of Rochester Medical Center in New York.

While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testing modalities, noninvasive colon cancer screening is becoming more accessible than ever. Join host Dr. Peter Buch and Dr. Aasma Shaukat as they discuss the effectiveness of current and emerging methods as well as best practices for screening patients. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine at the NYU Grossman School of Medicine and the Co-Director of Translational Research, Education, and Careers and the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU.

Racial and ethnic bias prevent patients with colorectal cancer from receiving the highest quality of care. Dr. Neil Nandi is joined by Dr. Fola May, Assistant Professor of Medicine at UCLA, to discuss racial inequalities in access to care and screening for patients with colorectal cancer.

Screening for colorectal cancer is unique because there are several screening options available. So how can we balance the latest ACG Clinical Guidelines with patient preferences, cultural context, and insurance coverage to find the best screening option for our patients? Joining Dr. Peter Buch to discuss the updated recommendations is Dr. Aasma Shaukat, lead author of the 2021 ACG Clinical Guidelines for colorectal cancer screening.

From new guideline recommendations to a concert featuring the American College of Gastroenterology’s official band, a lot is being done to help raise awareness of the importance of screening for colorectal cancer. So how can you help increase screening rates in your own community? Get inspired with these creative initiatives shared by Dr. Neil Nandi and Dr. Samir Shah, President of the American College of Gastroenterology.

Adenoma detection rate (ADR) may help us better detect our patients’ risk of developing colorectal cancer. To explore what we need to know about this quality indicator, Dr. Peter Buch joins Dr. Aasma Shaukat from the New York University Grossman School of Medicine to talk about ADR.